Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients

Blood

Volumn 88, Issue 1, 1996, Pages 358-365

  Sutton, Laurent ^a   Chastang, Claude ^b   Ribaud, Patricia ^b   Jouet, Jean Pierre ^b   Kuentz, Mathieu ^b   Attal, Michel ^b   Reiffers, Joseph ^b   Tigaud, Jean Marie ^b   Rio, Bernard ^b   Dauriac, Charles ^b   Legros, Michel ^b   Dreyfus, François ^b   Lioure, Bruno ^b   Troussard, Xavier ^b   Milpied, Noël ^b   Witz, Francis ^b   Oriol, Pascale ^b   Cahn, Jean Yves ^b   Michallet, Mauricette ^b   Gluckman, Eliane ^b   Ifrah, Norbert ^b   Pico, José Luis ^b   Vilmer, Etienne ^b   Leblond, Véronique ^b   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BLAST CELL; CHILD; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 8944243549     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.1.358.358     Document Type: Article

References (32)

1. Koeffler HP: Myelodysplastic syndromes (Preleukemia). Semin Oncol 23:184, 1986
2. Aul C, Gatterman N, Heyll A, Germing U, Derigs G, Schneider W: Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposal for an improved scoring system. Leukemia 6:52, 1992
3. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D: Myelodysplastic syndromes: A scoring system with prognostic significance. BrJ Haematol 59:425, 1985
4. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74:395, 1989
5. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report of 408 cases. Leukemia 7:1315, 1993
6. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497, 1991
7. Levin EG, Bloomfield CD: Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19:47, 1992
8. Aul C, Schneider W: The role of low-dose cytosine arabinosine and agressive chemotherapy in advanced myelodysplastic syndromes. Cancer 64:1812, 1989
9. Koeffler HP, Heitjan D, Mertelsmann R, Kolitz JE, Schulman P, Itri L, Gunter P, Besa E: Randomized study of 13-cis retinoic acid versus placebo in the myelodysplastic disorders. Blood 71:703, 1988
10. Gradishar WJ, Le Beau MM, O'Laughlin R, Vardiman JW, Larson RA: Clinical and cytogenetic response to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood 80:2463, 1992
11. O'Donnell JR, Nademanee AP, Snyder DS, Schmidt GM, Parker PM, Bierman PJ, Fahey JL, Stein AS, Krance RA, Stock AD, Forman SJ, Blume KG: Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 5:1822, 1987
12. De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lonnqvist B, Beelen D, Ferrant A, Gmur J, Liu Yin J, Troussard X, Cahn J, Van Lint M, Gratwohl A: Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes: A survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74:151, 1990
13. Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH: Bone marrow transplantation for myelodysplasia and secondary acute non-lymphoblastic leukemia. J Clin Oncol 8:1707, 1990
14. Appelbaum FR, Barrel J, Storb R, Fisher LD, Schoch G, Ramberg RE, Shulman H, Anasetti C, Bearman SI, Beatty P, Bensinger WI, Buckner D, Clift RA, Hansen JA, Martin P, Petersen FB, Sanders JE, Singer J, Stewart P, Sullivan KM, Whiterspoon RP, Thomas ED: Bone marrow transplantation with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 112:590, 1990
15. Nevill TJ, Shepherd JD, Reece DE, Barnett MJ, Nautel SH, Klingemann HG, Phillips GL: Treatment of myelodysplastic syndromes with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 10:445, 1992
16. Ratanatharathorn V, Karanes C, Uberti J, Lum LG, De Planque MM, Schultz KR, Cronin S, Dan ME, Mohamed A, Hussein M, Sensenbrenner LL: Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81:2194, 1993
17. Sutton L, Leblond V, Le Maignan C, Jouet JP, Kuentz M, Gluckman E, Blaise D, Marit G, Attal M, Troussard X, Bordigoni P, Cahn JY, Ribaud P: Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: Outcome of 86 patients. Bone Marrow Transplant 2:39, 1991 (suppl 7)
18. Andersen JE, Appelbaum FR, Storb R: An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymph 17:95, 1995
19. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips JL, Sanders J, Stroncek D, Thomas ED, Blume KG: Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 328:593, 1993
20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (FAB Cooperative Group): Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189, 1982
21. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Lum L, Martin P, Mc Guffin R, Sanders J, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68:119, 1986
22. Maraninchi D, Gluckman E, Biaise D, Guyotat D, Rio B, Pico JL, Leblond V, Michallet M, Dreyfus F, Ifrah N, Bordigoni P: Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukemias. Lancet 2:175, 1987
23. Sullivan KM: Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 4:42, 1986
24. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
25. Cox DR: Regression models and life tables. J R Stat Soc 34:187, 1972
26. Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, Besinger XI, Bryant E, Buckner CD, Doney K, Martin PJ, Sanders JE, Sullivan KM, Thomas ED, Witherspoon RP, Hansen JA, Storb R: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677, 1993
27. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Mirai H, Hiroshima K, Hotta T, Kuramoto A, Kuriga S, Miyazaki T, Kakishita E, Mizogerchi H, Okada M, Shirekawa S, Takaku F, Tomonaga M, Uchino H, Yasunaga K, Nomura T: Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7:499, 1993
28. Geller RB, Saral R, Piantadosi S, Zahurak M, Vogelsang GB, Wingard JR, Ambinder RF, Beschorner WB, Braine HG, Burns WH, Hess AD, Jones RJ, Stratford May W, Rowley SD, Wagner JE, Yeager AM, Santos GW: Allogeneic bone marrow transplantation after high dose busulfan and cyclophosphamide in patients with acute non-lymphocytic leukemia. Blood 73:2209, 1989
29. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382, 1987
30. Clift RA, Buchner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994
31. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, Milpied N, Attal M, Michallet M, Ifrah N, Kuentz M, Dauriac C, Bordigoni P, Gratecos N, Guilhot F, Guyotat D, Gouvernet J, Gluckman E: Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 79:2578, 1992
32. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, Jacobsen N: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the nordic bone marrow transplantation group. Blood 83:2723, 1994